

WILSON SONSINI




MARCH 16-17, 2023

EVENT PROGRAM CLEONE PETERSON ECCLES ALUMNI HOUSE

UNIVERSITY OF UTAH

PRESENTED BY







DRIVEN TO DISCOVER



At University of Utah Health, our world-class researchers work together to tackle some of the toughest problems in health and medicine. With scientists down the hall from health care providers, and across campus from leading-edge scholars, we're uniquely positioned to turn big ideas into real solutions. From gene therapies to health apps to AI-driven diagnostics, we're taking discoveries from bench to bedside and advancing care in clinics and communities to improve lives in Utah and beyond.





uofuhealth.utah.edu/research





WELCOME TO THE 2023 ENTREPRENEUR & INVESTOR LIFE SCIENCES SUMMIT


On behalf of BioUtah, BioHive and the University of Utah's PIVOT Center, we welcome you to the 8th annual Entrepreneur & Investor Life Sciences Summit (Summit). We host this Summit for many reasons including; introducing investors to the life sciences industry in Utah, showcasing exciting investable technologies being developed here, connecting companies and investors, providing content to assist early-stage companies and networking between various segments of our life sciences community – one of the fastest growing in the country.

This year we are placing a particular emphasis on companies seeking funding. We not only have six excellent companies chosen for the pitch competition, but we have over 20 other companies who have a presence in our virtual Pitch Hall accessible through the Whova app. The fact we only chose six companies to present in the pitch competition does not mean there are only six companies worth considering. We encourage you to explore all the companies seeking funding that have provided information through our virtual platform.

Networking is always highlighted as the main reason attendees come to this event. We encourage you to make use of the Whova app where all attendees are listed. You can communicate with other attendees and even invite them to meet with you. You will notice that we have many "networking areas" shown on the map of the facility including some high boy tables with numbers on them in the front room of the main floor by the registration desk. Invite another attendee to meet you at a specific table number.

We are grateful for the generous support of our sponsors and exhibitors who make the Summit possible, particularly Wilson Sonsini, our title sponsor. We also thank the many investors who have taken the time to be here today and learn more about the state's burgeoning innovation hub. We value your participation as we continue to brand, build and unite Utah's life sciences community. Together, we are paving the way for an even brighter future. Enjoy the day!

Kelvyn Cullimore, Jr.	Keith Marmer, DPT, MBA
President & CEO	Chief Innovation and Economic Engagement Officer
BioUtah	University of Utah





BOARD OF DIRECTORS

CHAIR ANDREA KENDELL BIOMÉRIUEX

VICE CHAIR MYLES GREENBERG ALUCENT BIOMEDICAL

PAST CHAIR BRAD BROWN ATL TECHNOLOGY

NATE ARNIM EDWARDS LIFESCIENCES

ERIN BARRY MERIT MEDICAL SYSTEMS, INC.

KATE BENEDICT

KOLBY DAY POLARITY TE, INC.

CHRIS GIBSON RECURSION PHARMACEUTICALS

KEITH MARMER UNIVERSITY OF UTAH

JAY MUSE PIPER ACCESS

BO NEMELKA INTERMOUNTAIN HEALTH

MICHAEL OLSON ZIONS BANK

MARK PAUL STRYKER NEUROVASCULAR

RANDY RASMUSSEN RIP BIOSCIENCE

BOARD ADVISOR JEFFREY KIMBELL JEFFREY J. KIMBELL & ASSOCIATES

PRES & CEO KELVYN H. CULLIMORE JR. BIOUTAH

TREASURER JB HENRIKSEN AMPLEO

LEGAL COUNSEL JACEY SKINNER JD BALLARD SPAHR




REPRESENTING UTAH'S LIFE SCIENCES INDUSTRY

UTAH HAS THE FASTEST GROWING LIFE SCIENCES INDUSTRY IN THE NATION SINCE 2012



NATIONALLY FOR LIFE SCIENCES' SHARE OF WORKFORCE



JOIN TODAY AT BIOUTAH.ORG

Source: Pace, Levi, Spolsdoff, Joshua. "Economic impacts of Utah's Life Sciences Industry." Kem Gardner Policy Institute, University of Utah, 2018. **VENUE LAYOUT** CLEONE PETERSON ECCLES ALUMNI HOUSE, UNIVERSITY OF UTAH



WIFI & WHOVA APP



WIFI INSTRUCTIONS

- 1. Choose "UGuest" from the list of available networks
- 2. Open a browser and go to "onboard.utah.edu"
- 3. Agree to "Terms & Conditions"
- 4. Choose "Guests"
- 5. Follow the on-screen directions, entering an SMS-capable phone number or verification code obtained from a University sponsor

Need Help?

If you need help, call the UIT help Desk at 801.581.4000 option 1 or visit it.utah.edu.



Search "Whova" in the App Store on your iPhone or in Google Play on your Android phone. Open the app and search for "entrepreneur and investor." Once you have found the E&I Summit, sign in using the same email you used to register for the Summit. If you do not have a password, please create one by entering it in the appropriate field.

Post-Event Content Access

Content can be accessed for up to three months after the Summit using the online app or the mobile app.



SUMMIT COMPANION APP: **WHOVA**

The E&I Summit uses the Whova platform to enrich your experience at the Summit while delivering all sessions virtually. Whova will also allow you learn about speakers and sponsors, engage with exhibitors, view poster presentations from participating companies, schedule meet ups with attendees, and more. Whova can be accessed via both an online app and a mobile app.

Online App

The online version of Whova can be accessed at eilifesciencessummit.org by clicking the "Whova Access" link. Login using the email address with which you registered for the Summit.





SESSIONS:

MORNING / PITCH / SHOWCASE

ENTREPRENEUR / FINANCE HENRIKSON

MORNING SESSION

MARCH 16, 2023

CLEONE PETERSON ECCLES ALUMNI HOUSE, UNIVERSITY OF UTAH

7:30 AM	NETWORKING CONTINENTAL BREAKFAST	SPONSORED BY	
8:30 AM	WELCOME AND OPENING REMARKS KEITH MARMER, UNIVERSITY OF UTAH; KELVYN CULLIMORE,	J.P.Morgan	
	BIOUTAH; AIMEE EDWARDS, BIOHIVE		
8:45 AM	CEO PANEL: ACHIEVING SUCCESS IN THE LIFE SCIENCES		
	Moderator: Alison Johnson, Wilson Sonsini dan Lemaitre, Bluewind Medical; rob etherington, Clene Nanomedicine;		
	DAVID BEARSS, HALIA THERAPEUTICS; ANDREA MAZZOCCHI, KNOWN ME		
9:30 AM	STATE OF VENTURE CAPITAL IN LIFE SCIENCES		
	MODERATOR: KAREY BARKER, CROSS CREEK ADVISORS		
	JAMES BUXTON, NEA; ART PAPPAS, PAPPAS CAPITAL; ISRAEL ROLLINS, ALIGNED HEALTH VENTURES; JENNY BARBA, FEATURES CAPITAL		
	VENTORES, JEININT BARBA, TEATORES CATHAE		
10:15 AM	BREAK		
10·30 AM	MARKET OVERVIEW		
10.00 AM	MONICA DICENSO, JP MORGAN		
11:15 AM	PERSPECTIVES BEYOND VENTURE CAPITAL		
	MODERATOR: NOLA MASTERSON, SCIENCE FUTURES MANAGEMENT CO.		
	CHRIS MCFADDEN, KKR; GEOFFREY LOOS, CAPM ADVISORS; CHRIS LIPUMA,		
	FORTRESS CAPITAL; CHRIS MAYO, LONDON STOCK EXCHANGE GROUP		
12:00 PM		SPONSORED BY	
	NETWORKING LUNCH		



SESSION LOCATION:

PITCH / SHOWCASE

PITCH TRACK & COMPANY SHOWCASE

MARCH 16, 2023

CLEONE PETERSON ECCLES ALUMNI HOUSE, UNIVERSITY OF UTAH HOSTED BY LISA DUNLEA, FORMER LIFE SCIENCES EXEC & VENTURE CAPITALIST

РІТСН	COMPETITION	SPONSORED BY		
1:00 PM	PITCH COMPETITION 3HELIX, MIKE KIRKNESS	Morgan Stanley		
	BIRCH OS, SCOTT MADSEN			
	PHOENIX PHARMALABS, BILL CROSSMAN			
	FOCUSED THERAPEUTICS, MYLES GREENBERG NANOSPOT.AI, RIAN WENDLING			
	NVIEW MEDICAL, CRISTIAN ATRIA			
	JUDGES: SYLVIA MCBRINN, MARSHALL DAHNEKE,			
	IVY ESTABROOKE, MIKE FREEMAN, JEREMY BUZZARD			
2:30 PM	BREAK			
COMPANY SHOWCASE				
2:45 PM	COMPANY SHOWCASE DISCGENICS, ROBERT WYNALEK PIPER ACCESS, JAY MUSE EPITEL, MARK LEHMKUHLE OWLET, KURT WORKMAN RENALYTIX, JAMES MCCULLOUGH			
4:00 PM	FEDERAL GOVERNMENT AND INNOVATION: AN OXYMORON? BRIAN FAHEY, LEGISLATIVE DIRECTOR, REP. BRETT GUTHRIE (KY-02), U.S. HOUSE OF REPRESENTATIVES			



SESSION LOCATION:

FINANCE / ENTREPRENEUR HENPIKSON

FINANCE & ENTREPRENEUR TRACKS

MARCH 16, 2023 CLEONE PETERSON ECCLES ALUMNI HOUSE, UNIVERSITY OF UTAH

HOSTED BY MATT BRESNAHAN, WILSON SONSINI

FINANCE TRACK

SPONSORED BY

FREEDOM APITAL MARKETS

- 1:00 PM **EARLY-STAGE FINANCING OPTIONS** MODERATOR: MARCIA NELSON, FREEDOM CAPITAL MARKETS BRUCE ROBERTS, GLOBAL BIOACCESS FUND; ZESHAN MUHAMMEDI, MBX CAPITAL; RACHEL BUTLER, CATALYTIC IMPACT FOUNDATION
- 1:45 PM DRIVING INNOVATION IN UTAH: THE UTAH INNOVATION FUND **MODERATOR: KELVYN CULLIMORE, BIOUTAH** JEFFERSON MOSS, UTAH SYSTEM OF HIGHER EDUCATION & UTAH STATE LEGISLATURE; KEITH MARMER, UNIVERSITY OF UTAH; GABI TELLEZ, UTAH SYSTEM OF HIGHER EDUCATION
- 2:30 PM BREAK

ENTREPRENEUR TRACK

- 2:45 PM VALUE: CREATE IT, PROTECT IT, MAXIMIZE IT ADRIAN BEAMISH, PARTNER CAPITAL MARKETS AND DEALS, PWC; DON HULET, MANAGING DIRECTOR ASSURANCE AND TRUST SOLUTIONS, PWC; TYSON WOODRUFF, MANAGING DIRECTOR CYBERSECURITY AND ENTERPRISE RISK, PWC; BRIAN BABCOCK, MANAGING DIRECTOR STRATEGIC VALUATIONS AND DUEDILIGENCE, PWC 3:30 PM WHY IS YOUR COMPANY INVESTABLE: MARKETING YOUR COMPANY STORY
 - CHELLI MILLER, CONTENT CARNIVORES; JEFF WALKER, CONTENT CARNIVORES; DAVE POLITIS, THE DAVE POLITIS COMPANY; JACK BOREN, EPIC VENTURES









SESSION LOCATION:

G2G CONSULTING

UTAH INNOVATION CENTER PUGH BUSINESS CENTER

SCHEDULE AN APPOINTMENT WITH A NON-DILUTIVE FUNDING EXPERT

ONE-ON-ONE APPOINTMENTS



G2G CONSULTING LIZ POWELL, FOUNDER & PRESIDENT

G2G is a premier Washington D.C. based firm that specializes in identifying non-dilutive federal grants for life sciences companies. They have helped clients secure over \$320M in federal funding since 2007. Meet with G2G principal, Liz Powell, and learn about federal grant opportunities that may fit your needs.

SCAN QR CODE TO SCHEDULE APPT. WITH LIZ



ONE-ON-ONE APPOINTMENTS



UTAH INNOVATION CENTER LINDA CABRALES, DIRECTOR

The Utah Innovation Center works with entrepreneurs in their journey to develop and advance innovative technologies and is in awe of the remarkable talent and drive found in Utah. They support businesses in accessing non-dilutive funding through the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.

SCAN QR CODE TO SCHEDULE APPT. WITH LINDA



APPOINTMENTS AVAILABLE ON A FIRST-COME, FIRST-SERVE BASIS



SKI DAY

MARCH 17, 2023 DEER VALLEY RESORT, PARK CITY, UT



SKI DAY SCHEDULE

- 7:30 AM CONTINENTAL BREAKFAST GOLDENER HIRSCH, 7520 ROYAL ST., PARK CITY, UT 84060 COMPLIMENTARY VALET PARKING (FIRST COME, FIRST SERVE)
- 9:00 AM SKIING
- 12:00 PM LUNCHEON GOLDENER HIRSCH, 7520 ROYAL ST., PARK CITY, UT 84060

LIFT TICKETS

SCAN QR CODE FOR LOCATION AND PARKING INFORMATION, OR TO PURCHASE DISCOUNTED LIFT TICKETS AND REGISTER FOR THE LUNCHEON.



SCHWEGMAN IS A PROUD SPONSOR OF BIOUTAH E&I SUMMIT

SKI DAY

Schwegman is a vibrant and innovative law firm dedicated exclusively to the practice of intellectual property law. Our 110+ intellectual property attorneys and agents serve a roster of clients that includes startups, universities, multinational corporations, middle-market businesses, and individuals in matters spanning the entire technical spectrum including those relating to digital healthcare, biotechnology, pharmaceuticals, and medical technology.



MINNEAPOLIS | SAN JOSE

SUMMIT PARTICIPANTS



CRISTIAN ATRIA CEO, nVIEW MEDICAL

Cristian is a healthcare entrepreneur with 25 years of experience in product development and commercialization. He founded nView Medical after a successful career with GE Healthcare where he developed and launched three major imaging systems and was General Manager for the surgical navigation business. He had commercial and R&D roles at Fiagon (Germany) and HealthTronics (Austin, TX). He holds two Masters of Science degrees in Engineering from renowned universities in Europe, an MBA from Boston University and an Entrepreneurship certificate from MIT. Cristian spends his free time with his family or in the outdoors climbing, mountain biking, or skiing.



BRIAN BABCOCK MANAGING DIRECTOR - DEALS VALUATION, PWC

Brian is a managing director in PwC's Deals practice in Rockies and has over 17 years of experience specializing in the valuation of business enterprises, equity instruments, and intangible assets for financial reporting, tax and strategic purposes, including assessing deal value in connection with strategic acquisition, divestitures and joint ventures.



JENNY BARBA

CO-FOUNDER, MANAGING PARTNER, FEATURES CAPITAL

Jenny Barba, Co-Founder and Managing Partner of Features Capital, is a venture investor with over twenty-four years of experience financing the growth of medical device and healthcare technology innovation. Jenny has executed over \$4 billion in capital transactions across thirty lead-managed public and private equity offerings, M&A, and alternative investments. Jenny specializes in deal sourcing, portfolio construction, harvesting growth and building management teams in medical technology companies across all stages of development and a broad spectrum of diseases.



KAREY BARKER FOUNDING MANAGING DIRECTOR, CROSS CREEK ADVISORS

Karey is a generalist with broad public and private investment experience. She is interested in great business models across sectors and has led investments in a variety of industries, including digital marketplaces and consumer internet, health-care technology and services, marketing software and services, and other enterprise software and services. New areas of interest include manufacturing and supply chain innovation and sustainable product innovation.



ADRIAN BEAMISH PARTNER, PWC

Adrian is a Deals Partner in PwC's Health Industries Practice with over 30 years of experience advising life sciences and technology companies ranging from emerging companies to publicly owned large multinationals. He is experienced in advising clients on issues relating to capital market and M&A transactions, IPO readiness, complex accounting and reporting matters, financial statements, finance processes and controls.



DAVID BEARSS CHAIRMAN AND CEO, HALIA THERAPEUTICS

Dr. Bearss is a passionate and experienced entrepreneur with a successful track record of drug development that spans the last 25 years in both academic and pharmaceutical industry settings. He has discovered 16 compounds that have moved forward in clinical development and started many biotechnology companies, including Tolero Pharmaceuticals in Lehi, Utah which sold for nearly \$1 billion, a state life sciences record. In addition to his current leadership at Halia Therapeutics, Dr. Bearss serves on the board of Biolexis Therapeutics, Canary Speech and Galvan Health and helped start the U2TAH Therapeutics Accelerator at the University of Utah.

MASCHOFF BRENNAN IS PROUD TO SUPPORT THE 2023 E& LIFE SCIENCE SUMMIT

PROTECTING YOUR IDEAS AND YOUR BUSINESS.

Maschoff Brennan is a leading Intellectual Property & Litigation law firm with more than 35 attorneys. Our team offers a range of technical and legal expertise in a variety of fields, and is committed to protecting and promoting the intellectual property interests of 801.297.1850 our clients throughout Utah.



PARK CITY | SALT LAKE CITY | IRVINE | LOS ANGELES



JACK BOREN MANAGING PARTNER, EPIC VENTURES

Jack is a career venture capitalist with a passion for identifying and backing visionary entrepreneurs. Over the past decade, Jack has worked with a variety of disruptive healthcare and biotech companies including Recursion Pharmaceuticals (NASDAQ: RXRX), Collective Medical Technologies (ACQ: PointClickCare), Conversa Health (ACQ: American Well Corp), Marketware (ACQ: Medsphere Systems), Unlearn.ai, Healthjoy, Teiko Bio and more. Jack is involved in various industry organizations and advocacy groups including the Rocky Mountain Venture Capital Association. Prior to EPIC, Jack worked for Cisco Systems in the Corporate Development Finance Group. He holds a BS in finance from the University of Utah.Jack is an avid cyclist and can be found most mornings riding in one of the canyons along the Wasatch Front.



MATT BRESNAHAN PARTNER, WILSON SONSINI

Matt Bresnahan is a partner in the San Diego and Los Angeles offices of Wilson Sonsini Goodrich & Rosati, where he has focused his practice for the past fifteen years on establishing and building biotech companies. Matt also spends a significant amount of time in the firm's new Salt lake City office. Matt's training is in all aspects of intellectual property, including strategic patent counseling, patent prosecution, licensing, and litigation. Matt is primary outside IP counsel to more than 50 life sciences companies within the biotechnology, therapeutic, genomics, and medical device fields in Southern California. Matt leads a team of more than 30 patent attorneys and patent agents at the firm.

workman nydegger Intellectual Property Law

YOUR IDEA IS ONE OF A KIND.

So is our approach to intellectual property law. Our custom, hand-tooled solutions give your idea a craftsman's touch from day one.

We have a passion for what we do — we are craftsmen of our trade. As engineers, scientists, and developers, we'll understand your invention, and we'll take a creative approach to protect and enforce your work using all facets of intellectual property rights including patents, trademarks, copyrights, trade secrets, litigation and more.

60 E. South Temple Suite 1000 Salt Lake City, UT 84111 801.533.9800 | wnlaw.com





RACHEL BUTLER PRESIDENT, CATALYTIC IMPACT FOUNDATION

As President of the Catalytic Impact Foundation, Rachel Butler has extensive experience and expertise analyzing, evaluating, and investing in early- and mid-stage companies in the life sciences and healthcare industry. Since 2016, she has reviewed hundreds of such companies and served as a team leader, overseeing and managing the research, analysis, and investment processes, to select companies for presentation and/or investment, beginning at Cavendish Global and then at Catalytic Impact Foundation. She is a lead member of the investment team that invested in the CIF portfolio of innovative healthcare companies. Previously, she served as co-founder and Editor-in-Chief of Asthma Magazine, a patient education publication for asthma and allergy.



JAMES BUXTON PRINCIPAL, NEA

James joined NEA in 2021 and is currently a Principal on the healthcare team, where he focuses on investment in the life sciences space. Prior to NEA James worked at SR One Capital Management where he focused on early stage biopharma opportunities. Prior to SR One he worked at Morgan Stanley and New Rhein Healthcare Investors. He began his career as a practicing physician and then as a surgeon focused on Cardiothoracic surgery, having joined the Royal College of Surgeons with his MRCS. During medical school he spent time researching endothelin signaling in colorectal cancer, driving to Mongolia for charity and lived in Samoa working at the national hospital.





JEREMY BUZZARD CO-FOUNDER AND PARTNER, INDUCTION BIO

Jeremy did his PhD and post-doctoral training in cellular and molecular biology at Monash and Harvard respectively. He subsequently spent 12 years at McKinsey, where he co-led the firms global healthcare strategy and transactions practice. After McKinsey, he has worked in senior leadership of a number of startups, and also led strategy and M&A for Danaher's diagnostics platform. Jeremy is now building a portfolio of businesses in Utah as a partner in Induction Bio.



LINDA CABRALES DIRECTOR, UTAH INNOVATION CENTER

Linda Cabrales is the Innovation Center Director at the Utah Governor's Office of Economic Opportunity. She works with entrepreneurs and researchers to develop and advance innovative technologies and supports businesses throughout the state to access non-dilutive funding through the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Linda has worked in communications and marketing, management consulting, investment banking, and co-founded a successful small business.



BILL CROSSMAN CEO, PHOENIX PHARMALABS

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation. Mr. Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences. Mr. Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets.

A History of Innovation

McCarter English

With advanced degrees and hands-on experience in the fields driving the life sciences industry, McCarter lawyers deliver innovative solutions for enterprises at every stage of development.

www.mccarter.com



KELVYN CULLIMORE PRESIDENT & CEO, BIOUTAH

Kelvyn has three decades experience as a medtech CEO, over a decade on the board of the Medical Device Manufacturers Association and over a decade as mayor of a suburb of Salt Lake City. He brings a unique understanding of industry and policy issues to advance Association objectives and help member companies. He has been CEO of BioUtah since October 2018.



MARSHALL DAHNEKE OPERATING PARTNER, GRIDIRON CAPITAL

Marshall Dahneke is an Operating Partner with Gridiron Capital LLC based in New Canaan, CT and serves as a Director on Boards with five companies. Previously, Marshall served as Chief Executive Officer and Chief Commercial Officer of Performance Health (Akron, OH) from June 2008 until April 2018. Prior to joining Performance Health, Mr. Dahneke was Vice President and GM of the Infection Prevention Technology business at STERIS Corporation as well as the Vice President, New Venture Development at Hillenbrand industries. His career also includes over a decade at Hill-Rom. He started his career as a Consultant with Bain & Company, Inc. in their Boston, MA office.



MONICA DICENSO HEAD OF GLOBAL INVESTMENT OPPORTUNITIES GROUP, JPMORGAN PRIVATE BANK

Monica DiCenso is a Managing Director and Head of the Global Investment Opportunities Group (GIO) at J.P. Morgan Private Bank based in New York City. GIO provides investment advice to the firm's most sophisticated clients and family offices around the world by facilitating institutional level implementation across asset classes. Prior to joining GIO in 2015, Monica was the Head of U.S. Equity Strategy at J.P. Morgan Global Wealth Management where she managed a team of strategists and served as a key resource for clients by identifying equity ideas including thematic brokerage and options trades as well as identifying single stock selections for our recommended trading lists. Monica joined the Private Bank in 2012 from J.P. Morgan's Investment Bank.

LIFE SCIENCES IN SLC

We are leading together. Salt Lake City is building a world-class Healthcare Innovation Center — intentional space for more incubator, office, and wet lab locations where startups can grow and scale with ease.



For more information, reach out to Technology and Innovation Advisor Clark Cahoon at clark.cahoon@slcgov.com or visit our website.



SLC.GOV/ED



LISA DUNLEA FORMER LIFE SCIENCES EXEC & VENTURE CAPITALIST

Lisa has over 25 years of experience in life sciences as a venture capitalist and entrepreneur, focusing on digital health, therapeutics, diagnostics, and devices. In her current role with the University of Utah's PIVOT Center as a part-time senior executive, she helps the organization with presenting and financing promising spinout life science technologies.



AIMEE EDWARDS EXECUTIVE DIRECTOR, BIOHIVE

Aimee Edwards is the Executive Director of BioHive leading the organization's mission to brand, build and bring together the life science and healthcare innovation ecosystem. She has a broad range of leadership experience building community, branding and policy. Prior to joining BioHive, she served as the External Affairs Director at Western Governors University. In this role, she launched the university's first community affairs department which was vital in securing national partnerships, expanding social impact and advancing education and workforce development programs. She previously held multiple positions of increasing responsibility at the Utah Governor's Office and Utah Governor's Office of Economic Opportunity including leading strategic outreach, communications and marketing, and legislative strategy.

MAYER | BROWN A tech-savvy law firm

We're global

because disruptive ideas enjoy world travel.

"Mayer Brown's clients include start-ups, major pharmaceutical, biotech and medical device companies, financial institutions, funds and other investors."

—The Legal 500 US



Get to know us: mayerbrown.com



IVY ESTABROOKE SENIOR INNOVATION POLICY STRATEGIST, RTI INTERNATIONAL

Ivy Estabrooke has focused on accelerating the development and adoption of emerging technologies across public and private sectors. She currently is a Senior Innovation Policy Strategist at RTI International where she works to strengthen regional and biomedical innovation programs. Prior to joining RTI, she held leadership positions at two biotech start-ups, led Utah's technology based economic development and as a program officer for the Office of Naval Research. She serves as an independent director of a public critical materials company. She holds a doctorate in neuroscience from Georgetown University, a masters in national resource strategy from the Eisenhower School of National Security Strategy and Resource Management, and a bachelors in biology from Smith College.



Supports Utah's Life Sciences Industry By:

- Providing assistance to access non-dilutive funding for R&D projects.
- Offering microgrants and non-recourse loans for technology development.
- Presenting training and workshops to support small businesses.



Contact Us: Innovationutah@utah.gov | business.utah.gov/innovation



ROB ETHERINGTON CEO, CLENE

Rob Etherington is the founding CEO of Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company pursuing drug therapies for Multiple Sclerosis and Amyotrophic Lateral Sclerosis. As CEO of Clene, Rob raised ~\$115M privately and ~\$18M in grants/direct support to fund Clene's drug development efforts prior to taking CLNN public on the NASDAQ in late 2020. Rob started at Pfizer, where he was a Team Leader for the drug Lipitor. He joined Actelion Pharmaceutical in 2000 to be the founding commercial leader; Actelion became the largest EU biopharm until Johnson & Johnson purchased Actelion. Rob is a past Board member of BioUtah.



BRIAN FAHEY LEGISLATIVE DIRECTOR, US HOUSE OF REPRESENTATIVES

Brian serves as Legislative Director and health care policy adviser to U.S. Congressman Brett Guthrie, who chairs the Energy & Commerce Committee Health Subcommittee. Before joining Representative Guthrie's office, Brian worked as a Senior Legislative Assistant for Congressman John Curtis (UT-03), staffing the Congressman specifically on health care policy and technology policy. Brian is a native Delawarean and graduated from the University of Delaware in 2014 with a degree in Political Science.

WILSON SONSINI

Partners in Discovery and Innovation

Wilson Sonsini represents life sciences companies at all stages, from formation to exit, and has one of the largest life sciences practices in the United States. For more than 40 years, our attorneys have worked closely with scientists, entrepreneurs, and investors who have helped develop new and innovative discoveries in nearly every field of medicine and healthcare, from genomics, immuno-oncology, and pharmaceuticals to diagnostics and synthetic biology.

Life Sciences Leadership

The firm's life sciences practice features a multi-disciplinary team of attorneys, patent agents, and scientific advisors. We represent clients in a wide range of strategic and operational corporate areas and assist them with complex commercial and technology transactions driven by IP and innovation.

For more information, visit wsgr.com.

Attorney Advertising

Wilson Sonsini has 19 offices in technology and business hubs worldwide. For more information, visit **wsgr.com/offices**.



MIKE FREEMAN GENERAL PARTNER, INNOSPHERE FUND II

Mike Freeman is the Chief Executive Officer of Innosphere Ventures. Innosphere Ventures is a multi-faceted organization with a 25-year-old science and technologyfocused incubator, specialized facilities for R&D-intensive startup ventures, and venture capital. Mr. Freeman is responsible for all Innosphere operations, finances, strategy, and execution. Mr. Freeman is the General Partner in Innosphere Ventures Fund I and Fund II and has led multiple investment rounds in science and technology companies in Colorado and surrounding states.



MYLES GREENBERG CO-FOUNDER, FOCUSED THERAPEUTICS

Dr. Myles Greenberg has more than 20 years of experience in growing healthcare, medical technology and biotechnology firms as an entrepreneur, operating executive, board member, clinician and investor. In addition to the board of Focused Therapeutics, he currently serves as CEO of Alucent Biomedical, a clinical-stage company developing a novel therapy for vascular disease. Previously, Dr. Greenberg was both an operating executive and partner in three healthcare venture capital funds. In addition, he currently serves as vice chair of the BioUtah board and as an entrepreneur-in-residence in the Center for Medical Innovation at the University of Utah. Dr. Greenberg began his career as a faculty physician and clinical director at Beth Israel Deaconess Medical Center in Boston.

2023 E&I Life Science Summit Michael Venture Best

Michael Best^{*} is proud to support the Entrepreneur and Investor Life Science Summit 2023.

Our experienced Venture Best' team works closely with entrepreneurs, start-ups, and early-stage companies to help you find the financial backing you need to take your vision to the next level — and our attorneys help entrepreneurs and investors navigate complex transactions, secure IP protection, and offer sage advice on a range of legal matters.

Michael Best & Friedrich LLP

Colorado | Ilinois | North Carolina | Texas | Utah | Washington, D.C. | Wisconsin

michaelbest.com



DON HULET MANAGING DIRECTOR - ASSURANCE SERVICE, PWC

Don is a managing director in PwC's Salt Lake City office and has over 30 years of experience in public accounting. Don serves clients primarily in the biotech, medical device and health industries sectors. He has extensive experience serving both public and private companies at various points in their life cycle, from emerging growth companies, venture-backed entities, those on the IPO journey, to large, multinational corporations. Don coordinates PwC's services to the life sciences companies here in Utah. He holds BA and MAcc degrees from Utah State University and is a licensed CPA in Utah.



MIKE KIRKNESS CEO, 3HELIX

Mike is a first-time biotech CEO, with a strong background in science and entrepreneurship. He earned a PhD in molecular biology and biochemistry with a focus on the biophysics of collagen from Simon Fraser University. He has bought and sold one previous company for a 4.5x return on investment, additionally he started two other companies and flipped multiple houses while finishing his PhD. With a strong belief in relationship development and being true to his word, Mike strives to run a company to help improve society through best-in-class science, integrity and capital efficiency.



ALISON JOHNSON CORPORATE PARTNER, WILSON SONSINI

Alison G. Johnson is a corporate partner at Wilson Sonsini Goodrich & Rosati, where she focuses on the representation of emerging companies at all stages of growth, advising them on venture capital and other financings, mergers and acquisitions, private equity, and corporate governance matters. She also represents venture capital firms and angel investors.





A PARTNER FOR INNOVATORS

Bringing a medical device to market is quite challenging, but Prime Path Medtech[™] simplifies the journey with exceptional service and a committed team of industry experts.

Regulatory Quality Clinical Fractional Staffing

Your Success is Our Success!

primepathmedtech.com info@primepathmedtech.com

Success is not an accident. That's why the right financial partner is so important.

At **J.P. Morgan Private Bank**, we know that building success is a process for life science and healthcare founders and executives. It begins by working with you to understand your individual circumstances and long-term goals. Then we develop and manage your plan to meet those objectives. Together, we work to help you achieve success on your terms.

CONNECT WITH US

Glade Morley 201 South Main Street, Suite 300 Salt Lake City, UT 84111 801.715.7323 jpmorgan.com/utah

J.P.Morgan

PRIVATE BANK

PLAN INVEST BORROW BANK

INVESTMENT PRODUCTS: • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE

© 2023 JPMorgan Chase & Co. All rights reserved.



MARK LEHMKUHLE CEO, EPITEL

Mark Lehmkuhle is CEO of Epitel. Epitel is revolutionizing how brain health is monitored. We are dedicated to improving seizure monitoring and detection. Our first commercial product, the REMI Remote EEG Monitoring System, is FDA cleared for near real-time and/or remote EEG monitoring. By leveraging our proprietary cloudbased wearable sensor system, we are enabling informed treatment decisions by making EEGs readily deployable and accessible at point-of-care.



DAN LEMAITRE CEO, BLUEWIND MEDICAL

Dan Lemaitre joined BlueWind Medical as Executive Chairman in September 2018 and serves as CEO since January 2020. Dan also serves on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~\$700 million per annum. Previously, Dan was the CEO of CoreValve that launched the first commercial transcatheter aortic valve in Europe in 2007. Prior to joining CoreValve, Dan was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development. Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.

The 9990 Group



Based in Salt Lake City, we are an experienced, multidisciplinary team who serves a clientele of accomplished entrepreneurs, their families and their business enterprises. Combining our own talents with the global resources of Morgan Stanley, we deliver comprehensive wealth management solutions to help our clients grow their wealth, establish the basis for an enduring legacy and pursue their vision of a meaningful life.

Working daily with successful business owners and executives, we are intimately familiar with the personal and professional challenges of growing and monetizing a successful venture. This experience enables us to serve as close family advisors who help our clients make well-informed and timely decisions.

We look forward to hearing from you.

Eric.Smith@morganstanleypwm.com 801.322.7663

Morgan Stanley

PRIVATE WEALTH MANAGEMENT



CHRIS LIPUMA DIRECTOR, FORTRESS INVESTMENT GROUP

Mr. LiPuma is a Vice President based in San Francisco in Fortress's Intellectual Property Group, where he focuses on a wide variety of investment opportunities in connection with intellectual property, life sciences, and academic institutions. Prior to joining Fortress in 2018, Mr. LiPuma headed business development for Kastle Therapeutics, a private equity backed biotechnology company acquiring ultra-orphan drugs. Before joining Kastle he was with OrbiMed Advisors, a life sciences focused asset management firm. At OrbiMed he worked on royalty monetizations, direct lending to late development stage and early commercial stage life sciences companies, and several private equity transactions focused on acquiring legacy assets from big pharma.



SCOTT MADSEN DIRECTOR OF BUSINESS DEVELOPMENT, BIRCH OS

Scott is an entrepreneur who has spent his 17 year career in business development, building technology companies which service highly regulated indices. He is also a cofounder of Birch Operating Systems.



GEOFFREY LOOS MANAGING DIRECTOR, CapM ADVISORS

Geoffrey Loos is a Managing Director with CapM Advisors, advising clients on a variety of complex and highly successful transactions in the healthcare, consumer and technology sectors. Mr. Loos' 20 years of transactional experience covers mergers, acquisitions, divestitures, corporate investments, public and private capital raises, PIPEs, debt placements and other valuecreating transactions. Prior to CapM, Mr. Loos was with D.A. Davidson's investment banking group. Prior to D.A. Davidson, Mr. Loos was a founding member of the University Venture Fund. Mr. Loos continues to actively supports Utah's business community through his involvement with MountainWest Capital Network and Utah's Association for Corporate Growth.

PROUD TO SPONSOR Wilson Sonsini and BioUtah's

Entrepreneur & Investor Life Sciences Summit

MARCH 16, 2023 SKY DAY MARCH 17, 20

Content Carnivores is a boutique digital agency specializing in regulated industries in pharmaceutical, biotech, med tech and other select industries



KEITH MARMER CHIEF INNOVATION & ECONOMIC ENGAGEMENT OFFICER, UNIVERSITY OF UTAH

As chief innovation & economic engagement officer at the University of Utah, Keith has transformed the culture of innovation at University of Utah, launching three technology accelerators, an incubator, a seed grant fund, and a venture fund. Keith has also helped impact Utah's innovation economy by working with Utah's legislature to vision and launch an innovation district at The Point. His strong leadership skills come from over 30 years of experience as an entrepreneur, investor, and innovation leader. He has launched four companies, and helped entrepreneurs raise more than \$1 billion in investment capital. Across his career, Keith has launched, help to launch or overseen teams responsible for starting more than 150 companies as well as hundreds of licensing transactions with global companies and venture capital firms. Previously, Keith was co-founder of SG3 Ventures, an early-stage venture capital fund. Prior to SG3, Keith was chief business officer at Penn Center for Innovation, University of Pennsylvania. Before his university-based commercialization roles, he was an entrepreneur, founding and scaling four companies. Keith serves and has served on numerous corporate and nonprofit boards including University Economic Development Association and is a past executive-in-residence at Princeton University. He received an MBA, Doctor of Physical Therapy, Master of Physical Therapy and Bachelor of Science in Health Sciences from St. Joseph's University.



NOLA MASTERSON MANAGING DIRECTOR, SCIENCE FUTURES MANAGEMENT CO. LLC

Ms. Masterson has had an extensive career in venture capital investments, as an entrepreneur and as an investor. She was the first biotech analyst on Wall Street, and cofounder of Sequenom. She was a trailblazer for women in corporate sales management at Millipore and Ames. She is a venture partner at Portfolia Femtech Funds and works with Boardwise to train, and advise board of directors. She sits on three start up boards and one publicly traded biotech board. She is a published author and frequent speaker. Her hobbies include horseback riding and oil painting.



CHRIS MAYO HEAD OF PRIMARY MARKETS, AMERICAS, LONDON STOCK EXCHANGE GROUP

Chris helps companies and investment managers from the Americas access capital through corporate equity and fund listings on London's public markets. He has 25 years of corporate finance experience in New York and London for Barclays, Salomon Smith Barney, Citi and Schroders and has executed IPOs, financings and M&A transactions in the US and Europe worth tens of billions of dollars. Previously, Chris was the Primary Markets specialist on the technology and life science sectors and was also an investor and Head of Strategy for an early-stage cloud managed services company, which exited to a UK technology company. He holds a First Class Honours Bachelors Degree in International Business and German from Aston University, a Masters Degree in International Affairs from Columbia University and is a CFA Charterholder.



ANDREA MAZZOCCHI CEO, KNOWN MEDICINE

Andrea Mazzocchi, PhD is a co-founder and CEO of Known Medicine, which aims to improve the lives of cancer patients. Dr. Mazzocchi completed her PhD in Biomedical Engineering from Wake Forest School of Medicine and has spent the past decade creating novel cancer tissue engineered models. She has focused on the intersection of biomaterials and cancer biology to co-found Known Medicine a cancer precision medicine platform, merging patient-specific organoids with data science to generate biological, computational, and clinical insights to improve cancer patient lives.



SYLVIA McBRINN BOARD DIRECTOR, STRATEGIC ADVISOR TO A VC, ANGEL INVESTOR, RETIRED CEO

Sylvia McBrinn has more than 40 years of leadership and commercialization experience in the biopharmaceutical industry. She currently serves as a board director at BioAtla (BCAB) and Ilya Pharma (a Private Swedish Biotech Co) Ms. McBrinn also advises innovators at Yale University as an Entrepreneur in Residence and female entrepreneurs as a member of the Life Science Council of Springboard Enterprises. She is also a strategic advisor for PropelBio (Venture Capital) and an Angel Investor. She was the founding CEO of Axerion Therapeutics, a private clinical stage biotech company. Ms. McBrinn began her career at Pfizer where she held sales and marketing leadership roles including Vice President, Global and US Marketing.



PROJECT DELIVERY, EVOLVED.

PROTECSINC.COM (833) PRO-1900

CONSTRUCTION MANAGEMENT, DESIGN/BUILD AND INTEGRATED PROJECT DELIVERY

Specializing in: Cleanrooms, Manufacturing, Pharmaceutical, Medical Device, Specialty Chemical, Advanced Materials, Food and Beverage ,Wet/Dry Labs, cGMP Warehouses, Higher Education, Life Sciences Office, Data Centers, Healthcare

SALT LAKE CITY, UT 801-441-7744 ext. 414

RALEIGH, NC PLYMOUTH MEETING, PA NEWARK, DE BRIDGEWATER, NJ



JAMES McCULLOUGH CEO, RENALYTIX

James McCullough is Renalytix's Chief Executive Officer, with primary focus on strategic planning and execution, as well as coordination with key stakeholders. James has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. James was most recently chief executive officer of Exosome Diagnostics, a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer. James is also a managing partner of Renwick Capital, LLC ("Renwick"), a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution.



CHELLI MILLER VP CLIENT SERVICES/PARTNER, CONTENT CARNIVORES

Chelli began in healthcare, managing the presenting company-side of a small-cap/private investor conference that ran simultaneously to the JP Morgan Healthcare Conference. This allowed her to build a reputation that provided an unprecedented reach into new and evolving Life Science tech, innovative marketing and communications platforms, related investor world, and strategic relationships.

> C DDRSEY[™] always ahead

ready, set,

Dorsey & Whitney is

Proud to Support the

2023 Entrepreneur and

Investor Life Sciences Summit.



CHRISTOPHER McFADDEN MANAGING DIRECTOR, KKR

Christopher McFadden is a Managing Director with Kohlberg Kravis Roberts (KKR) in San Francisco where he leads the firm's healthcare finance practice. Mr. McFadden's career includes senior healthcare investing roles with Goldman Sachs, Health Evolution Partners and Canyon Healthcare Partners. He has held board positions with both sponsorowned and publicly traded healthcare companies and is a founding member of the COVID Patient Recovery Alliance. Mr. McFadden holds a Bachelor's degree from the University of Richmond and is a Chartered Financial Analyst (CFA).



JEFFERSON MOSS ASSOCIATE COMMISSIONER OF INNOVATION, EXECUTIVE DIRECTOR OF THE INNOVATION DISTRICT AT THE POINT, UTAH SYSTEM OF HIGHER EDUCATION

Jefferson Moss is The Point's Innovation District Project Director. In this capacity, he leads USHE's involvement in the major economic development efforts at The Point. Moss is responsible for overseeing the strategic initiatives and dayto-day operations at the Innovation District. He will work in close consultation with The Point Executive Director and Operations Director to help implement practical solutions that improve Utahns' quality of life. Formerly, Moss served as AVP of central advancement at UVU and the COO for the UVU Foundation. In these positions, he launched the UVU Wolverine Fund, a student-run venture capital fund, and the Excellence and Innovation Initiative. Prior to UVU, Moss served as a wealth strategist at Key Bank and Credit Suisse and launched several successful businesses. He received his Bachelor of Arts in Political Science and Master of Business Administration from Brigham Young University. He currently serves in the Utah House of Representatives and previously served on the Utah State Board of Education and the Saratoga Springs City Council and Planning Commission.



ZESHAN MUHAMMEDI CO-FOUNDER, MANAGING PARTNER, MBX CAPITAL

Zeshan is a founder and Managing Partner of MBX Capital where he invests in Public Health companies across life sciences, health-tech and services. MBX Capital is a boutique venture capital firm that partners with and creates healthcare and biotechnology companies that are disrupting conventions in service to public health. MBX focuses primarily on early-stage companies that are inventing in overlooked domains of knowledge or which are harnessing edge effects to instigate quantum leaps in their fields. The firm is headquartered in New York City and was founded in 2020.



Experience Counts

Navigate Capital Markets with Confidence

Freedom Capital Markets (FCM) offers clients tailored solutions to help fuel growth, including IPOs and follow-on offerings, shelf offerings, rights offerings, PIPEs, SPACs, private placements, convertible issues, and more. We provide investment banking, finance, and capital markets services advisory to corporate and institutional clients worldwide. FCM is the investment banking and equity capital markets arm of Prime Executions, Inc., a wholly-owned subsidiary of Freedom Holding Corp. (NASDAQ – FRHC)

> 40 Wall Street, 58th Floor New York, NY 10005 <u>www.freedomcapmkts.com</u>



JAY MUSE PRESIDENT & CEO, PIPER ACCESS

Jay is an Operating Partner with the Med Venture Holdings group. He is currently President and CEO of Piper Access, LLC, a vascular access company and Talon Medical, LLC (DBA Talon Surgical), a heart access company. He has 27 years of experience in innovation, engineering, technology development, and commercialization. Jay is passionate about developing medical devices that are loved by both clinicians and patients. Prior to the Piper Access and Talon Surgical, Jay worked for GE, IOMEGA, BD, & BARD in the management of product innovation & technology development. He currently resides in Salt Lake City, UT where he enjoys backcountry skiing and mountain biking.



MARCIA NELSON MANAGING DIRECTOR, FREEDOM CAPITAL MARKETS

Marcia is a Managing Director at Freedom Capital Markets (FCM), and President of Freedom Family Office, currently under development. Marcia has spent a large portion of her career working in and for family offices and private dealmakers. Prior to FCM, Marcia was a Managing Director and head of business development for ShareNett, a members-only global network of professional investors, and she worked previously at Alberleen Family Office Solutions, an independent investment advisory firm backed by family offices. She formerly worked for an ultra-high-net-worth philanthropic family as well as a sports and entertainment family. Over the last 20 years, she has developed a strong network of private families, institutional investors, and advisers who are increasingly seeking access to quality direct deal flow from trusted, experienced partners.

Ballard Spahr is a destination law firm for life sciences companies of all stages and innovation in Utah.

We are proud to sponsor the Entrepreneur & Investor Life Sciences Summit.





ART PAPPAS CEO AND MANAGING PARTNER, PAPPAS CAPITAL

Art is an experienced entrepreneur and venture capital investor, and former pharmaceutical and biotechnology industry executive. He founded Pappas Capital in 1994 and since then has raised over \$800 million. Prior to Pappas Capital, Art held senior leadership positions at Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and the Dow Chemical Company. Art is currently a director for Allievex and Sorriso Pharmaceuticals. He also serves on several non-profit boards, including the North Carolina Biotechnology Center, the Duke Cancer Institute and The Wistar Institute. He is a decorated Vietnam veteran, having served in the US Army 101st Airborne Division and 2nd PSYOP Airborne JFK Special Warfare Center.



LIZ POWELL FOUNDER & PRESIDENT, G2G CONSULTING

Liz Powell, Esq., MPH started G2G Consulting in 2007 after working as policy staff on Capitol Hill. G2G has raised \$524 million in non-dilutive funding for clients (many in health innovation), shaped regulations and policies, and organized advocacy campaigns. G2G produces the monthly GBG Report and Webinars listing life science government grants. Liz previously served as Legislative Director in Congress, campaign staff, Public Affairs Manager for a national health association, and Policy Analyst for the UK Parliament's Health Committee. She helped launch the Women's Health Innovation Coalition and serves on the Innovation Equity Forum Steering Committee run by the NIH Office of Research on Women's Health and the Bill & Melinda Gates Foundation.




DAVID POLITIS PRESIDENT & CEO, THE DAVID POLITIS COMPANY

David Politis helps inventors, entrepreneurs, and executives determine the best way to succeed with their ideas and change the world in the process. With strategic positioning, messaging, public relations, and marketing, he transforms such breakthrough ideas as spider-venom-based drugs, MP3 player technologies, and electric bicycles into multibillion-dollar products, services, and industries. A graduate of Brigham Young University, David has helped create over \$1.1 billion in increased market value for his clients, and he currently consults through The David Politis Company. Most recently he was VP, Content: Silicon Slopes; Chief Marketing Officer/Acting CEO: PersonAbilities; and Vice President of Marketing: Axcend.

THORPE • NORTH • WESTERN •

Intellectual Property Law

Trademarks Patents Copyright Ligitation





BRUCE ROBERTS MANAGING DIRECTOR, RM GLOBAL PARTNERS

Bruce Roberts is a Managing Director of RM Global Partners LLC, a specialized life sciences banking and investment firm he co-founded with a 25-year history. At RM Global, Bruce is a managing partner of the firm's Global BioAccess Fund. Bruce also is a General Partner of the RMGP Bio-Pharma Investment Fund, which invests in innovative biopharma start-ups in Israel in collaboration with JNJ, Takeda, Bayer and Orbimed. He is the manager of Select Medical Opportunities Management, LLC, which structures special purpose investment vehicles for disruptive medical technology in the RM Global ecosystem. He is Vice Chairman of Nectero Medical, a company developing treatments for vascular aneurysm disease, a board member of Control Medical Technology, and managing partner of Health Family Capital, LLC.



GABI TELLEZ CONSULTANT, UTAH SYSTEM OF HIGHER EDUCATION

Gabrielle or "Gabi" Tellez is a consultant with the Utah System of Higher Education working on The Point. She is also an investment analyst with Intermountain Ventures. Prior to Intermountain Ventures, Gabi worked with Intermountain Healthcare's Foundry, the health systems internal innovation program. She has also worked at Leavitt Partners as a health policy consultant. She is published in the Journal of Pediatric Surgery as a result of her work in the fetal surgery department at the Children's Hospital of Philadelphia. She has presented her work on streamlining patient flow through the post anesthesia care unit at Keck Hospital of USC at numerous conferences and helped illustrate a book on Lean Healthcare Systems Engineering. She has volunteered with Operation Smile as a health systems strengthening researcher, where she analyzed the health systems of twenty African countries and provided recommendations on how the organization can better serve the respective countries.




ISRAEL ROLLINS MANAGING PARTNER, ALIGNED HEALTH VENTURES

Israel Rollins is Managing Partner of Aligned Health Ventures where he leads the fund's investment activities. Prior to Aligned, Israel served as a Venture Partner at Sandbox Industries' Blue Venture Fund. Prior to Sandbox, Israel served as Managing Principal of Bethesda Capital Partners, LLC and as acting-CEO of its portfolio company, Nuline Sensor, LLC until its merger with InvisionHeart, LLC. Prior to Bethesda, Israel co-founded PharmMD LLC (acquired by Riverside Partners). Prior to that, Israel served in a number of roles with HCA including Associate Administrator, North Austin Medical Center, Director, Internet Strategy & Business Development, and Investor Analyst, Investor Relations. Israel holds a BS in Pharmacy from Florida A&M University, an MBA from Howard University, and an MPA from Harvard Kennedy School.



JEFFREY WALKER CEO, CONTENT CARNIVORES

As a business and creative leader for over 30 years, Walker's expertise is grounded in marketing fundamentals and innovation. Success in big tech for Monster.com, global marketing at Leo Burnett, and the entertainment business in Hollywood led him to found Content Carnivores in Chicago in 2013. Using a combination of technology efficiencies and human expertise, the company has helped hundreds of biotech, medtech, and hard tech businesses achieve their goals. For the last year, the Carnivores field office in Utah has been an exciting next chapter in our growth.



Positively impacting society.

PIVOT Center serves as a hub for the University of Utah to foster partnerships between industry, university, and government entities. The center formalizes the university commitment to broaden its impact on Utah's economy by enhancing local and global collaborations to catalyze innovation.

pivotcenter.utah.edu



RIAN WENDLING CEO, NANOSPOT.AI, INC.

Rian Wendling serves as the CEO at NanoSpot.ai. He has been developing and commercializing startup medical innovations for seven years. Prior to joining NanoSpot. ai, Rian was a Senior Global Product Manager of Future Panels at BioFire Diagnostics. Before that, he was the VP of Product Realization at ReddyPort, a non-invasive ventilation medical device company where he invented, produced, gained regulatory clearance on, and supported commercial efforts for the ReddyPort suite of products. He is a medical device developer who has designed and brought a wide array of devices to market, from single-use disposables to complex electrical devices.



KURT WORKMAN CEO, OWLET

Kurt Workman is the CEO of Owlet Baby Care based in Lehi, Utah. Owlet works towards a future where every parent, new and expecting, has access to better tools and information at the right time to care for their baby in the home. Kurt co-founded Owlet with a team of passionate parents in 2013 with a mission to revolutionize the way we care for our infants. Their most important accomplishment has been helping families be there for their child when it mattered most. Owlet has garnered many recognitions and awards including Best Baby Monitor of 2017, The Bump's Best in Baby Tech, listed as Forbes "Next Billion Dollar Company" and as founders on their "30 under 30" list. The company has also won multiple innovation awards at the Consumer Electronics Show (CES). Owlet went public on the New York Stock Exchange in July 2021.



TYSON WOODRUFF MANAGING DIRECTOR, PWC

Tyson Woodruff is a Managing Director in the PWC Cybersecurity practice. Tyson works with clients to help mature their cyber security and threat management capabilities in a way that aligns with and supports business operations. Since joining PwC, Tyson has served clients in many industries, to include Healthcare, BioPharma, Finance, and Technology. Tyson brings a broad range of experience in the public and private sectors, first as an FBI Special Agent and CIA Intelligence Officer, then later in the financial services and insurance industries. Tyson graduated from BYU and Univ. of Hawaii.



ROBERT WYNALEK CHIEF OPERATING OFFICER, CHIEF COMMERCIALIZATION OFFICER, AND BOARD DIRECTOR, DISCGENICS

Bob Wynalek is the chief operating officer, chief commercialization officer, and board director at DiscGenics, Inc. He is a medical device and biopharma professional and entrepreneur with 35 years experience within the regenerative medicine, spine, neurosurgical, and orthopedic markets. Mr. Wynalek has successfully built and re-built organizations, inclusive of experience with early stage organizations. Executive and functional leadership experience in general management, sales, marketing, product development, business development, clinical, and operations disciplines.

PITCH COMPANIES

SESSION LOCATION/TIME:

MAIN HALL

3Heli💥

3HELIX, INC. MIKE KIRKNESS 3HELIX.COM

3Helix, a revenue generating seed stage company with a first-of-its kind platform technology called Collagen Hybridizing Peptides (CHPs) which allow for the targeting of damaged collagen. 3Helix's lead products are an atopic dermatitis therapeutic, cosmetics active ingredients and NASH diagnostic.



BirchOS SCOTT MADSEN

BirchOS is the first Pharma ERP build around serialization compliance. It was built for Pharma by Pharma. BirchOS confirms serialization compliance, inventory compliance, licensing, payments, inventory management, CEO dashboards, licensing and many more features.

NanoSpot.ai

NANOSPOT.AI, INC. RIAN WENDLING NANOSPOT.AI

NanoSpot.ai is an artificial intelligence-driven medical diagnostic platform leveraging a unique agglutinationbased (i.e. "blood clumping"-based) approach to provide low-cost, accurate, and quantitative antibody measurements to the point of care.



nVIEW MEDICAL CRISTIAN ATRIA NVIEWMED.COM

nView medical is a commercial stage surgical imaging company; Our technology is a surgical imaging platform that provides instant 3D imaging, navigation, and data to improve surgery.

FOCUSED THERAPEUTICS

FOCUSED THERAPEUTICS MYLES GREENBERG

Focused Therapeutics is a start-up medical device company developing Focused Electric Field (FEF) technology for use in cardiac ablation procedures for the treatment of arrhythmias. FEF technology is designed to address a significant unmet need in the \$8B rapidly growing cardiac ablation market.



PHOENIX PHARMALABS BILL CROSSMAN PHOENIXPHARMALABS.COM

Phoenix PharmaLabs has a portfolio of drugs under development with unique opioid receptor characteristics that do not produce the euphoric "high" that leads to abuse and addiction, while still treating moderate to severe acute and chronic pain without the dangerous side effects found in other opioids.

PARTICIPATING COMPANIES

3DIO, INC. DOUGLAS HANSEN 3DTEETH.COM

The 3Dio Lumos 3DX intra-oral dental imaging system brings rapid, easy-to-use 3D diagnostic imaging to the patient in the chair. Lumos 3DX will set a new diagnostic standard in daily dental care.

ADCURA, INC ERIC BLOSSEY

ADCURASPINE.COM Precise patient solutions to improve outcomes in spinal surgery.

BIOLEXIS THERAPEUTICS

MICAH HARMAN BIOLEXISTX.COM

Biolexis Therapeutics is a biotech company committed to accelerating the development of NCEs by joining our proprietary data with ML/Al.

BLOOM SURGICAL JACOB SHEFFIELD

BLOOMSURGICAL.COM

Bloom Surgical empowers robotic laparoscopic surgeons to resolve intraoperative visual disruptions with an in-abdomen, rapid-response scope lens cleaning tool. Our device reduces time spent with compromised vision and scope removals, improving patient safety and procedure efficiency.

CARDIOST

NICOLAS ANZELLINI CARDIOST.COM

Cardiost is currently working on fully

implantable, mechanical circulatory support device to treat late-stage patients suffering from heart failure preserved ejection fraction (HFpEF). 3.1 million adults in the US have been diagnosed with HFpEF. It has NO device-based treatment approved by the FDA.

CMXTWENTY JOHN ZIEGLER, MD, FASA CMXTWENTY.COM

Early stage Pharma company with a first in class potent non-opioid non-NSAID analgesic product comparable in analgesic effect to opioids but with none of the undesirable side effects (such as respiratory depression, sedation, addiction, nausea, emesis, pruritis, etc.).

COUNTED LANCE SQUIRE COUNTED.COM

Counted has developed an inexpensive solution to the medication adherence problem. A solution that will provide real time accurate data, while minimizing any disruption in the current supply chain system. Providing real time data will enable providers to make better decisions.

DIAGNOSTIC VENTURES BRIAN BENTLEY DIAGNOSTICVENTURES.NET

Annually, sepsis affects 50 million people worldwide, with over 10 million deaths. Our patented process produces results in 2 hours which identifies the most dangerous antimicrobial resistant genes present in bacteria. Our product will help save lives and money.

HEALTHZONE C CORP.

BAB JAN

HUBONE.APP

Healthzone is raising the seed round. It is an app for the US Patients for international care, which provides EU International Surgery services to the US Patients for the lower cost of Surgeries, it's accessible at any time and convenient to use with much lower cost as compared to US and lesser waiting time. The Market size is USD 270 billion and we have the early mover advantage, having our potential existing network asset, superior Technology and superior Team. Healthzone developed the Technology, validated the concept and product from end users.

IMESSA RESEARCH SHOELEH ASSEMI IMESSARESEARCH.COM

Imessa Research manufactures a compact, innovative device for the precise and facile separation, purification and size analysis of nanoparticles used in vaccine preparation, drug delivery, theranostics, and imaging. The instrument cuts the analysis/purification time to minutes instead of days, and can be easily used by non-experts.

INHERENT BIOSCIENCES ANDY OLSON

INHERENTBIO.COM

Inherent Biosciences is on a mission to remove the guesswork in diagnosing complex issues starting in male reproductive health. The company's epigenetic platform detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics.

KENKO PHYSICAL THERAPY JOSEPH RAPAPORT

KENKOPT.COM

Kenko is an End-2-End platform that increases the physical therapy recovery rate by providing access and education for people suffering from chronic pain. A streamlined prescription process for physical therapists by increasing their operational efficiency and creating a continuum of engagement.

LIGHT LINE MEDICAL, INC. VICKI FARRAR

LIGHTLINEMEDICAL.COM

We are solving one of the greatest causes of morbidity and high cost in medicine today - infection from invasive catheters (dialysis, urinary, ventilators and vascular). Our patented visible light delivery system uniformly irradiates the internal and external surfaces of an indwelling catheter.

MAYA AI INC SAT RAMPHAL MEETMAYA.WORLD

Maya is a robotic brain built on the idea neuromorphic Ai, that uses generative Ai to answer any data question with comparatives to the real world, using your voice. We help pharma/healthcare develop treatment plans for patients in realtime, and re-purpose drugs for other uses.

PERFORMEXW

MARC LINDSAY

PERFORMEXW.COM

We have a therapeutic smart bandage wound care solution with integrated biosensors to continuously monitor and heal wounds. Our applications are civilian, military and veterinary, from general lacerations to diabetic ulcers, burn wounds and bacterial and fungal infections sustained by the military.

PIONEER BIOLABS JOSHUA YATES PIONEERBIOLABS.COM

Pioneer Biolabs is an early-stage biotech focused on strain optimization for recombinant protein production. To accomplish this, the company leverages high-throughput CRISPR techniques with fluorescent display systems. Pioneer targets fermentation-enabled companies in multiple protein industries.

PIXEL THERAPEUTICS INC. BRUCE CUMMINGS

Pixel is a mental health SaaS company to improve care for veterans and teens through clinical AI and real-time monitoring. Pixel has 30 patents on behavioral analytics.

PRECISION DROPPER JOEL DUSTIN

PRECISIONDROPPER.COM

At Precision Dropper we aim to promote eye health by removing barriers to taking eye medication. Did you know 60-80% of eye drop medication is wasted? This is because eye drops are 3-5 times too big for your eye and they are difficult to put in. After 37 revisions and 2 1/2 years of prototyping, we give you Precision Dropper. Precision Dropper is a universal eye dropper adaptor that reduces the size of eye drops while also increasing the ease of use.

QUANSYS BIOSCIENCES, INC.

ADAM BROWN QUANSYSBIO.COM

Quansys Biosciences specializes in customizable protein quantification by offering multiplex assays, imaging equipment, and user-friendly software analysis. Quansys maximizes data quality and quantity to accelerate the discovery, diagnosis, and treatment of disease.

REBEL MEDICINE BRETT DAVIS REBELMEDICINE.COM

Rebel Medicine is a pre-clinical specialty pharmaceutical company developing non-opioid solutions for acute pain management. Our flagship product is an injectable long-acting local anesthetic that can provide 72 hours of non-opioid postoperative pain management. It can be used in nearly any surgical procedure, either locally at the surgical site or injected as a nerve block agent. We're currently performing IND-enabling studies and preparing for our clinical program. We've raised a total of \$3M seed round and have received \$1.8M in non-dilutive grant funding from the NSF, NIH, and the State of Utah. We are currently seeking partners and investors for our clinical program beginning in 2024. Contact us for our pitch deck!

RHEUMAGEN RICHARD FREED RHEUMAGEN.COM

RheumaGen is an HLA gene editing company developing the cure for rheumatoid arthritis (RA) & other major autoimmune diseases. We have completed preclinical studies in RA and are preparing for IND submission in 2024.

SNOW CANYON THERAPEUTICS, INC. DAVID BLACKWELL

SNOWCANYONTHERAPEUTICS.COM

Snow Canyon Therapeutics is developing novel drugs for the treatment of chronic inflammatory diseases. By regulating redox, Snow Canyon has been able to stop all local chronic inflammation in a joint with osteoarthritis. This novel approach stops the progression of OA, restores a joint back to homeostasis and increases the thickness and density of cartilage. This technology will stop the need for joint replacements.

STINGRAY THERAPEUTICS ALEXIS WESTON STINGRAYTX.COM

Stingray is developing potent and selective small molecule inhibitors of ENPP1. ENPP1 is the direct negative regulator of the STING pathway which is essential for innate immune response. We have generated promising preliminary data and expect to file our IND in March 2023.

VIBE TECH UTAH MEGAN HANRAHAN VIBEWELLNESSLLC.COM

VIBE Tech Utah provides innovative, cutting edge, wearable technology solutions for active sports enthusiasts. Our product line is pioneered by CEO, Physical Therapist, Megan Hanrahan. We invite you to experience "Active Healing for your Active Lifestyle" where we optimize your injury recovery.

XENOCOR INC.

TONY WATSON

XENOCOR.COM

Xenocor is addressing the costs, risks, hassles and waste associated with traditional laparoscopic visualization that has gone largely unchanged since the 1980s. We are doing this through a single use platform that eliminates capital costs, certain risks, hassles, and actually reduces waste.

XENTHERA, INC. LYNNE KELLEY

XENTHERA.COM

Xenthera, headquartered in Salt Lake City, Utah, is a private clinical stage biopharmaceutical company founded in 2022, focused on oncology, discovering, and developing novel therapeutics for solid tumor oncology targets to improve the lives of patients fighting cancer. The leadership team has a strong record of developing drugs and devices from discovery through commercialization including multiple successful exits as well as extensive trial design and execution experience.

COMPANY SHOWCASE

SESSION LOCATION/TIME:

MAIN HALL 2:45 PM



DISCGENICS

ROBERT WYNALEK DISCGENICS.COM

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. We have recently received RMAT designation from the US FDA.

epitel

EPITEL MARK LEHMKUHLE EPITEL.COM

Epitel is revolutionizing how brain health is monitored. We are dedicated to improving seizure monitoring and detection. Our first commercial product, the REMI Remote EEG Monitoring System, is FDA cleared for near realtime and/or remote EEG monitoring. By leveraging our proprietary cloud-based wearable sensor system, we are enabling informed treatment decisions by making EEGs readily deployable and accessible at point-of-care.



OWLET KURT WORKMAN OWLETCARE.COM

Owlet makes wearable health devices for babies to help parents monitor what matters most. Over 2 million parents have trusted Owlet to help them better care for their baby and the company went public on the NYSE in 2021(OWLT).



PIPER ACCESS JAY MUSE PIPERACCESS.COM

Piper Access is a medical device company committed to providing superior vascular access products that are loved by both clinicians and patients alike. They are advocates of health and life, providing novel technologies to advance the frontier of medical innovation.



RENALYTIX JAMES McCULLOUGH RENALYTIX.COM

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs.



VISIT THE BOOTH OF THE EXHIBITORS LISTED BELOW

Ballard Spahr



MAYER BROWN





J.P.Morgan private bank













WILSON SONSINI

CHECK OUT THE ADDITIONAL ONLINE EXHIBITORS BELOW







THORPE • NORTH • WESTERN •





ELITE MEMBERS



BIOHIVE SUMMIT NOVEMBER.9.2023.

SAVE THE DATE SALT PALACE

PRESENTED BY

BIOUTAH Ebiohive